NCT02597114View on ClinicalTrials.gov

Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

PHASE1CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 19, 2018

Study Completion Date

August 2, 2018

Conditions

Mucopolysaccharidosis I

Interventions

DRUG

AGT-181

intravenous infusion over 3-4 hours

Sponsors

Lead Sponsor

All Listed Sponsors

lead

ArmaGen, Inc

INDUSTRY